Antivascular endothelial growth factor for choroidal neovascularization in pathologic myopia.
Choroidal neovascularization (CNV) is the most common vision-threatening macular complication in pathologic myopia (PM) being detectable in 4-11% of the affected eyes. Treatment of PM-related CNV is still controversial. Intravitreal injections of antivascular endothelial growth factor molecules are able to inhibit the vascular endothelial growth factor isoforms and have shown promise in the treatment of myopic CNV. The present review describes the beneficial effects of this approach both for subfoveal and juxtafoveal CNV. However, considering the lack of randomized clinical trials and the relatively short follow-up in most of the studies, a multicentric clinical trial should be necessary to validate the positive results in the long term.
Battaglia Parodi
Maurizio
M
Iacono
Pierluigi
P
Bandello
Francesco
F
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D005584:Fovea Centralis; D006801:Humans; D056965:Injections, Intraocular; D047728:Myopia, Degenerative / Q000150:complications*; D011379:Prognosis; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A